Advertisement
News
Advertisement

ImmusanT begins trials of celiac vaccine

Tue, 09/04/2012 - 12:00am
Mass High Tech: The Journal of New England Technology

Early-stage biotech business ImmusanT has started clinical trials in New Zealand, Australia and the U.S. to test Nexax2, a vaccine to treat patients with celiac disease, a condition that damages the lining of the small intestines and prevents it from absorbing specific parts of food.

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading